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240 An investigation into microbial contamination of non-invasive
ventilation (NIV) devices used in adults with cystic ﬁbrosis (CF)
S. Cameron1, P. Agostini1, A. Mutagi2, G. Abbott3, E. Boxall2, E.F. Nash1,
J. Whitehouse1, D. Honeybourne1. 1West Midlands Regional Adult Cystic
Fibrosis Centre, Heart of England NHS Foundation Trust, Birmingham, United
Kingdom; 2Health Protection Agency Laboratory, Birmingham, United Kingdom;
3Infection Prevention and Control Team, Heart of England NHS Foundation Trust,
Birmingham, United Kingdom
Background: Data for potential cross-infection risk of non-invasive ventila-
tion (NIV) use is limited. Our previous practice involved internal ethylene ox-
ide (ETO) sterilisation of NIV devices after use by CF adults with signiﬁcant airway
infection e.g. Burkholderia cepacia complex (BCC) or if outlet bacterial/viral ﬁlter
use not feasible (if integral humidiﬁer used). Changes in Trust sterilisation protocol
necessitated practice review.
Objective: To investigate levels of microbial contamination of patient environment
and NIV devices.
Method: Settle plates were placed and air sampling performed during airway
clearance in 2 patients, 1 Pseudomonas aeruginosa (PsA) and 1 BCC infected.
7 NIV devices (VPAP III and III/IV ST, BiPAP Harmony S/T) used by PsA or
BCC infected patients were swabbed in a controlled environment at 7 internal/
external sites, 5 devices pre- and 2 post-ETO sterilisation.
Results: Environmental ﬂora (>300 colonies) were cultured from 2 air sample
plates; settle plates had minimal growth (<11 colonies). Most swabs had no/minimal
growth (0−4 colonies). Exceptions: inlet ﬁlter housing of 1 device (pre-ETO); inlet
ﬁlter of another (post-ETO) which both grew >8 colonies of environmental ﬂora.
No common CF pathogens were isolated.
Conclusion: This small study shows no evidence of signiﬁcant NIV device contam-
ination, even without ETO sterilisation. Our centre has now ceased practice of ETO
sterilisation but uses separate devices for BCC infected patients. We now always:
use single patient use circuits with bacterial/viral ﬁlters (and separate single use
humidiﬁers); replace inlet ﬁlters and continue to surface clean devices between
patients.
241 When should lung function test be performed to evaluate the
effects of an airway clearance therapy session in children and
adults with cystic ﬁbrosis?
M.C. Rodriguez Hortal1, L. Hjelte1, M. Ortfelt1, H. Bergqvist1. 1Karolinska
University Hospital, Stockholm, Sweden
Objectives: Promoting airway clearance using chest physiotherapy remains a
mainstay of treatment for patients with CF. The aim of the respiratory physiotherapy
in patients with cystic ﬁbrosis is to mobilize and to evacuate the major quantity of
secretions to maintain or to improve the pulmonary function in order to slow down
the progression of the disease and to have a better quality of life.
Spirometry is often the tool to evaluate the effects of airway clearance techniques.
The aim of the study is to clarify at what time point after a treatment session
spirometry should be performed in order to obtain a reliable result and to ﬁnd out
whether there are inter and intra-individual differences.
Methods: 24 patients with CF (16 adults and 8 children) with mean lung function
FVC 70±30% and FEV1 61±30% of predicted were included. Each patient
performed a spirometry before; immediately, 30min, 1, 2 and 3 hrs after their
physiotherapy session. All the patients were measure twice to identify intra-
individual variation.
Conclusions: FEV1 and FVC in adults was statistically signiﬁcant improved 30min
after physiotherapy (p< 0.0003 and p< 0.02). FEV1 and FVC in children were not
statistically signiﬁcant but tendency was better immediately after the session. The
intra-individual variation for adults and children was not signiﬁcant.
There was a tendency showing that performing the spirometry immediately after
the session might be optimal in children and after 30minutes in adults (statistically
signiﬁcant). Adults have a worse disease status with morphological changes, and
a copious amount of sputum that may change the expectant time to perform
spirometry.
242 Effectiveness of universal tubing at generating positive
expiratory pressure in children: a pilot study
E. Carella1, B. Johnstone1, S. Brown2. 1Royal Hospital for Sick Children,
Glasgow, United Kingdom; 2Wishaw General Hospital, Glasgow, United Kingdom
Background: The physiological and clinical effects of Positive Expiratory Pressure
(PEP) have been well documented and are widely used for the therapeutic treatment
of respiratory conditions. The pressure delivered using Bubble PEP with tubing
of a small diameter has been suggested to be greater than the recommended
levels. (Mestriner et al. 2009). The aim the pilot was to determine the effects of
hospital suction tubing, with variable diameter, to deliver therapeutic pressures in
the treatment of Cystic Fibrosis (CF) children using Bubble PEP. We hypothesised
that the tubing would deliver pressures higher than the recommended levels to
recruit collateral ventilation.
Methods: This experimental in vivo study focused on CF children (N= 15) who use
Bubble PEP as part of their routine chest clearance. Bubble PEP was set up using
1 litre bottles of water at a water level of 10cms. Using Pennine healthcare 5mm
diameter non conductive link tubing, cut to a total length of 80cms. The diameter
of the tubing design varies between 5−10mm. A ‘Y’ connector attached the Druck
DPI 700(IS) manometer.
Conclusion: With the hospital-based bubble PEP set-up we found that 14 out of
the 15 (93%) children achieved peak pressures within the recommended therapeutic
range of 10−25 cms of water pressure. All of the children achieved the minimum
therapeutic pressures, however, one child exceeded these in all three attempts (see
poster table). The average pressure generated by the children was 21 cms of water
pressure. The link tubing delivered appropriate therapeutic pressure in children with
CF who routinely use Bubble PEP. Future research may include widening the patient
group to other respiratory conditions.
243 The tolerability of hypertonic saline in patients with cystic ﬁbrosis
N.M. Byrne1, C. MacLennan1, S. Rutter1, D.A. Spencer1. 1Great North Children’s
Hospital, Paediatric Respiratory Unit, Newcastle upon Tyne, United Kingdom
Hypertonic saline is commonly used as a mucolytic agent in patients with cystic
ﬁbrosis (CF). Evidence shows small short term improvements in lung function and
a reduction in the frequency of pulmonary exacerbations. Published studies have
used conventional jet nebulisers, but in current practice high output nebulisers such
as the e-ﬂow and I-neb are more commonly used. There is little data regarding the
use of these nebulisers with hypertonic saline.
Aim: to review current practice of administering hypertonic saline in the UK and
to ascertain any tolerability issues.
Method: A questionnaire was e-mailed to 36 adult and paediatric tertiary CF centres
in the UK. Questions related to the current use of hypertonic saline, types of
nebulisers used and tolerability issues.
Results: The response rate was 53%. 95% of centres used hypertonic saline as a
mucolytic agent, median number of patients per centre was 10 (1–100). All adult and
72% of paediatric centres used a bronchodilator pre dose. 88% of adult and 64% of
paediatric centres measured lung function at 1st dose. Issues with tolerability were
reported by 89% of centres. These included excess coughing, nausea, wheeze, sore
throat and regular stopping during the nebulisation period. Nebulisers included the
e-ﬂow, I-neb, Pariboy and side stream, with many centres using several of these.
58% of centres felt that the choice of nebuliser affected tolerability. This was due
to the higher output from the e-ﬂow and I-neb.
Conclusion: High output nebulisers are beneﬁcial as nebulisation time is reduced
and efﬁcacy may be improved but this needs to be balanced with tolerability issues.
Further research is needed in this area.
